Analyst Research

Report Title Price
Provider: Reuters Investment Profile
Provider: GlobalData

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Ablynx NV and Algeta ASA Enter Into a Research Collaboration to Evaluate Potential of Alpha-Pharmaceuticals Comprising Thorium-277 Conjugated to Tumour-Targeting Nanobodies

Wednesday, 21 Nov 2012 01:53am EST 

Ablynx NV and Algeta ASA announced a research collaboration to evaluate a Targeted Thorium Conjugate (TTC) based on combining Algeta's thorium-227 alpha-pharmaceutical payload with Nanobodies generated using Ablynx's technology platform. Under the terms of the collaboration, Ablynx will provide access to Nanobodies against a specific, undisclosed target and Algeta will provide access to chelation and conjugation technologies, as well as to its alpha-emitter thorium-227. Both companies will contribute resources towards the collaboration, which is expected to last for up to a year initially with the option for extension thereafter. No further terms have been disclosed. 

Company Quote

0.036 +0.45%
20 Oct 2014